EDAP high-intensity ultrasound therapy fails in Phase III interim data
French device company EDAP TMS has released interim data from the Phase III trial of its robotic high-intensity focused ultrasound…
French device company EDAP TMS has released interim data from the Phase III trial of its robotic high-intensity focused ultrasound…
Spanish fertility biotech, Oxolife has presented positive exploratory Phase II data for its non-hormonal fertility pill, OXO-001, in patients who underwent…
The female infertility market is expected to grow moderately from $1.6bn in 2023 to $2.3bn in 2033, at a compound…
Menarini has released results from a study showing that its non-invasive prenatal testing technology can detect foetal abnormalities with higher…
Great progress has been made in the management of female infertility since the introduction of assisted reproductive technology, predominantly in…
Bayer’s non-hormonal therapy elinzanetant met primary and secondary endpoints in two pivotal Phase III trials by reducing the frequency and…
Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…
Israel-based Gynica will dose the first patient in a Phase I trial of its cannabinoid-based therapies IntraVagS301 and IntraVagS302 for…
UK-based pharmaceutical company AstraZeneca has reported treatment benefits in findings from the DUO-E Phase III clinical trial of Imfinzi (durvalumab) plus Lynparza (olaparib).…
GSK has announced promising results from the Phase III RUBY/ENGOT-EN6/GOG3031/NSGO clinical trial of the programmed death receptor-1 (PD-1)-hindering antibody Jemperli…